Last updated: 2026-09-06 13:28:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Sagimet Biosciences Inc. (SGMT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $10.91, with a market capitalisation of $683.12M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.50 to $11.32. This page covers its latest market performance, valuation, price trends and company information.
$683.12M | |
$10.79 | |
$20.71 | |
$1.73 | |
$10.92 | |
1.09M | |
-- | |
-- | |
$11.32 | |
$4.50 | |
-- | |
-- |
Sagimet Biosciences Inc. (SGMT) last closed at $10.92 as of 2026-09-04 23:58:00, unchanged from the previous close of $10.92.
During the latest regular trading session, SGMT traded between $1.73 and $20.71, with a volume of 1.09M shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Sagimet Biosciences Inc. (SGMT) moved from $10.36 to $10.91, representing a gain of 5.32% ($0.55).
The stock traded between $10.53 and $11.32 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 980.78 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 94.0%
SGMT is currently trading at $10.91, placing it 94.0% of the way from its 52-week low of $4.50 to its 52-week high of $11.32. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 16 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Sagimet Biosciences Inc. (SGMT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.